Background: CD44 is a cell surface glycoprotein implicated in such diverse biologic processes as lymphocyte activation and homing, extracellular matrix adhesion, and cellular migration. Primary transcripts of the CD44 gene can be alternatively spliced to produce a variety of messenger RNA (mRNA) species. The standard form of CD44 mRNA contains sequences from at least 20 genomic exons; variant mRNAs contain sequences from one or more additional exons (v1-10). Predominant expression of a specific CD44 variant, i.e., CD44v8-10, in several human carcinomas has been described previously. In this study, we developed a novel molecular approach for detecting cancer cells that overexpress CD44v8-10 mRNA. Methods: After finding that CD44v8-10 was predominantly expressed in non-small-cell lung and bladder carcinomas and that CD44v10 was predominantly expressed in leukocytes, we developed a competitive reverse transcription-polymerase chain reaction assay (CC-RT-PCR) that allows quantification of the relative expression of these two mRNA species in clinical specimens (i.e., determination of a v8-10/v10 ratio). CC-RT-PCR analysis was applied to pleural effusion specimens from patients with benign or malignant lung diseases as well as to spontaneously voided urine samples from patients with benign or malignant urologic diseases. Results: Fifty two of 54 samples from patients with benign diseases expressed CD44v10 predominantly (v8-10/v10 ratio р0.65), whereas 46 of 61 samples from patients with malignant diseases expressed CD44v8-10 predominantly (v8-10/v10 ratio >1.00) (two-sided P<.001). CC-RT-PCR detected predominant expression of CD44v8-10 in cytologically negative samples from 11 patients who were later diagnosed with malignant disease. Conclusions: CC-RT-PCR analysis of CD44v8-10 expression could be an important adjunct to cytologic examination in cancer diagnosis, especially in detecting exfoliated cancer cells in pleural effusions and urine. [J Natl Cancer Inst 1998;90:307-15]
In cancer management, the burden falls on clinicians to establish a definitive diagnosis of cancer. Therefore, one goal of cancer researchers has been to develop tests that facilitate rapid and accurate diagnosis, leading to better prognosis in cancer patients.
Recently, various basic studies using the polymerase chain reaction (PCR) for the detection of cancer have been reported (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . However, PCR has not been applied practically in clinical cancer diagnosis. Hesitation in this regard may be caused by the following factors: 1) Although the choice of target for amplification is evidently determined by the specific characteristics of malignant cells, suitable common genetic targets for most solid tumors are rare (4) . Even minimal expression of the target gene in non-neoplastic cells makes it difficult to distinguish cancer cells from normal cells when transcripts are analyzed due to the extraordinary sensitivity of the PCR technique (10) . 2) Some of the reported methods devised for quantitative assays (12) or for the detection of mutations in either oncogenes or tumor suppressor genes (2, 3, 5, 6) are cumbersome and labor intensive. Their use as routine laboratory methods is not plausible.
3) The assessment of the clinical interpretation of the results of PCR assays used as new diagnostic methods has been unsatisfactory. For example, although cancer cells (1, 4) or DNA (8, 9) circulating in the blood were shown to be detected by PCR, the implication of the PCR detection in early cancer diagnosis or in the development of secondary disease is not fully understood. The results of PCR assays must be interpreted with great caution in clinical medicine to avoid the inappropriate management of patients.
CD44 is a widely distributed cell surface glycoprotein implicated in such diverse biologic processes as lymphocyte homing (13) , extracellular matrix adhesion (14) , leukocyte activation (15, 16) , and cellular migration (17) . The CD44 transcript is composed of at least 20 exons and 10 variant exons (v1-10), which can be alternatively spliced in various combinations, thereby generating numerous splice variants (CD44v) from a single gene (18, 19) . The CD44 standard form (CD44s) lacks all variant exons, and its encoded protein is expressed on cells of mesodermal and hemopoietic origin. CD44v expression has also been described in many normal tissues (20) (21) (22) (23) . Following the initial demonstration by Günthert et al. (24) that a CD44 splice variant containing variant exon 6 (CD44v6) could confer metastatic potential on rat pancreatic adenocarcinoma cells, a great deal of scientific interest has focused on CD44v expression in human carcinomas. Many investigators have demonstrated expression of specific CD44 variant exons in human carcinomas by Southern blot analysis of PCR products, using exon-specific probes, and immunohistochemical analysis, using exon-specific antibodies (23, (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) . However, the variant exons that have been associated with cancer have been detected in corresponding normal tissues in other studies (21, 22) . Thus, the biologic implications of CD44v expression in human tumors remain to be elucidated.
We examined CD44 variants predominantly expressed in human carcinomas by use of a reverse transcription-PCR (RT-PCR) analysis that employed primers immediately flanking the site of variant exon insertion in the CD44 open reading frame, followed by DNA sequence analysis. We previously reported that a specific CD44 splice variant, CD44v8-10, which contains variant exons 8, 9, and 10 (also referred to as CD44R1) is highly expressed in colon carcinomas compared with adjacent nonneoplastic tissues (44) . Since we reported this finding, other groups have also described the predominant expression of CD44v8-10 in various human carcinomas, including breast (34), gastric (41) , and thyroid (45) . To analyze CD44v8-10 expression further, in this study we examined the CD44 splice variants expressed in non-small-cell lung carcinomas (NSCLCs) and bladder carcinomas and confirmed that CD44v8-10 was the most dominant splice variant in these tumor tissues. Therefore, we investigated whether CD44v8-10 could be used as a marker in cancer diagnosis.
Here, we report the development of a novel molecular approach, CD44v8-10/CD44v10 competitive RT-PCR (CC-RT-PCR), for the detection of cancer cells overexpressing CD44v8-10. We applied this method to an initial population of pleural effusion and urine samples from patients and compared the results with results obtained by standard cytologic examination and with results of follow-up diagnostic tests for some of the cases that were cytologically indeterminate.
Materials and Methods

Cell Culture
The human colon adenocarcinoma cell line HT29 and the human bladder cancer cell line HT1376 were obtained from the American Type Culture Collection (Rockville, MD). The cells were grown in Dulbecco's modified Eagle medium with Ham's F-12 nutrient mixture (Life Technologies, Inc. [GIBCO BRL], Gaithersburg, MD) supplemented with 10% heat-inactivated fetal calf serum at 37°C in an atmosphere containing 5% CO 2 .
Patients and Specimens
Specimens of bladder and lung carcinoma and samples of corresponding adjacent normal tissue were obtained up to 20 minutes after surgical removal, snap-frozen in liquid nitrogen, and stored at −80°C until use. The presence of carcinoma cells in the carcinoma tissues was routinely confirmed by cryostat sectioning before analysis. Normal peripheral blood leukocytes used for control experiments were obtained from seven healthy volunteers. Peripheral venous blood (5 mL) was subjected to gradient isolation of nucleated cells by use of Polymorphprep (Nycomed, Oslo, Norway) and following the manufacturer's instructions. Isolated mononuclear and polymorphonuclear cells were used immediately for RNA extraction.
Pleural effusion samples were obtained from 41 patients with clinically proven carcinomatous pleurisy (36 non-small-cell lung carcinomas, two breast carcinomas, two gastric carcinomas, and one laryngeal carcinoma) and from 34 patients with benign pulmonary diseases (12 cases of tuberculosis, 14 cases of bacterial pneumonia, and eight others). Spontaneously voided urine samples were obtained from 20 patients with bladder cancer and from 20 patients with benign urologic diseases (10 cases of cystitis, eight cases of benign prostatic hypertrophy, and two cases of ureter stones). All samples were obtained during the course of routine diagnostic evaluation. For our research, informed consent was obtained from all patients. Cells from pleural effusions and urine were examined by both CC-RT-PCR and cytologic analysis. Cytologic analysis was performed in a blinded fashion, following normal clinical procedures. For the CC-RT-PCR analysis, pleural effusion (5-10 mL) or urine (50-100 mL) samples obtained from patients were stored at 4°C and subjected to RNA extraction within 4 hours. Samples were centrifuged at 500g for 10 minutes, and the supernatants were discarded. The precipitated cells were washed with phosphate-buffered saline (PBS) and used directly for RNA extraction. To ensure the successful completion of cDNA synthesis for each sample, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA was amplified with the following primers: sense, 5Ј-AAGGCTGGGGCTCATTTGCAG-3Ј and antisense, 5Ј-CCAAATTCGTTGT-CATACCAGG-3Ј. For the determination of CD44 splice variants expressed in tissue samples and normal leukocytes, we used the S1 sense primer (5Ј-TCCCAGACGAAGACAGTCCCTGGAT-3Ј) and the AS1 antisense primer (5Ј-CACTGGGGTGGAATGTGTCTTGGTC-3Ј), thereby immediately flanking the insertion site for the variant exons in the CD44 open reading frame. Direct DNA sequencing of PCR products was performed with the 373S DNA sequencer (Applied Biosystems, Foster City, CA), using standard protocols. CC-RT-PCR was performed using a set of primers (S2: 5Ј-GACAGAATCCCTGCTAC-CAATA-3Ј and AS2: 5Ј-ATGTGTCTTGGTCTCCTGATAA-3Ј) that can amplify both CD44v8-10 and CD44v10 cDNA. To prevent contamination and product carryover, disposable, cotton-plugged pipette tips were routinely used, and all procedures were performed in laminar-flow tissue culture hoods with UV lights on between experiments. Negative control reactions that did not contain a cDNA template were included in all experiments.
RT-PCR Analysis
Measurement of the CD44v8-10/CD44v10 Ratio
The amplification products from CC-RT-PCR were electrophoresed in 2% agarose gels and visualized by ethidium bromide staining and UV transillumination. The resulting images were then density scanned (ATTO Densitograph, model AE-6905, Macintosh version, ATTO, Tokyo, Japan). Band intensities for the areas corresponding to the amplimers of CD44v8-10 and CD44v10 were then determined by use of the NIH image 1.60 program (Wayne Rasband Analytics, National Institutes of Health, Bethesda, MD), and CD44v8-10/CD44v10 (v8-10/v10) ratios were calculated. The measurements were performed by one of us (T. Morisaki) without knowledge of the samples or the results of any other laboratory investigations. All samples were assessed in three independent PCR reactions, and the reported v8-10/v10 ratios represent the mean values from these triplicate determinations.
Immunohistochemical Analysis
Polyclonal antibodies against the CD44v8-10 protein were generated and purified by methods described previously (46) . In brief, New Zealand White female rabbits were immunized with a glutathione S-transferase (GST)-CD44v8-10 fusion protein, and the resulting anti-CD44v8-10 antibody was immunoaffinity purified on a GST-CD44v8-10 affinity column. Periodatelysine-paraformaldehyde-fixed, paraffin-embedded pleural tissues were cut into 6-m thick sections, which were mounted on glass slides; the sections were subsequently deparaffinized and rehydrated. The slides were rinsed in PBS, and endogenous peroxidase was inhibited by treatment with 0.3% H 2 O 2 in ethanol for 15 minutes. Immunoperoxidase staining was performed at room temperature by use of an avidin-biotin kit (Vector Laboratories, Inc., Burlingame, CA). Nonspecific staining was blocked by preincubation in a 2% solution of normal goat serum in PBS. The slides were next incubated in primary antibody (25 g/mL in PBS) for 1 hour. They were subsequently washed with PBS and incubated with a secondary, biotinylated, anti-rabbit immunoglobulin for 30 minutes, followed by an incubation with avidin-biotin-conjugated horseradish peroxidase for 30 minutes, with rinses in PBS between each step. The peroxidase substrate, 3,3Ј-diaminobenzidine tetrahydrochloride (DAB; 3 mg in 10 mL 0.05 M Tris-HCl [pH 7.6] in 0.01% hydrogen peroxide), was added, and the peroxidase reaction was allowed to continue for 5 minutes at room temperature. Excess DAB was then washed off for 5 minutes, and the slides were counterstained in hematoxylin and mounted with Crystal/Mount (Biomeda, Foster City, CA).
Statistical Analysis
The Mann-Whitney U test was used to estimate the significance of differences in CD44v8-10/CD44v10 ratios between malignant and benign samples. The level of statistical significance was set at P<.01 (two-sided).
Results
CD44v8-10: a Major Splice Variant Expressed in Human Tumor Tissues
Alterations in CD44 splicing patterns have been reported in various human cancers, and these findings have attracted widespread attention to CD44 as a candidate molecular marker for cancer diagnosis. With the multitude of controversies that have surrounded data on CD44 alternative splicing, we examined which CD44 splice variants were most frequently and dominantly expressed in human cancers. For this purpose, RT-PCR analysis, followed by DNA sequence analysis of the PCRamplified bands, was performed on frozen tumor tissue sections from NSCLCs and bladder carcinomas, using the S1 sense and AS1 antisense primers that are capable of amplifying all CD44 splice variants (Fig. 1, A) . As shown in Fig. 1 , B, CD44v8-10 was the most dominant splice variant expressed in these tumor tissues. These findings were consistent with our previous report on human colon carcinomas (44) and led us to examine a specific variant, CD44v8-10, as a marker for cancer diagnosis.
Development and Validation of CD44v8-10/CD44v10 Competitive RT-PCR (CC-RT-PCR)
We initially tried to identify small numbers of CD44v8-10-positive cancer cells in various body fluids, such as blood, urine, pleural effusions, and ascites, by amplifying CD44v8-10 tran- Schematic presentation of CD44 exons showing the positions at which primers S1 and AS1 anneal. Sequences homologous to S1 and AS1 are located in exons 5 and 16, respectively (arrows). The S1 and AS1 primers can be used for analysis of CD44 variant exon expression. B) RT-PCR amplification using primers S1 and AS1 on complementary DNAs (cDNAs) from surgical specimens of transitional cell carcinoma of the bladder (Bladder T), adenocarcinoma of the lung (Lung T), and their matched adjacent normal tissues (Bladder N, Lung N). The amplification products were electrophoresed in a 2% agarose gel and visualized by ethidium bromide staining and UV transillumination. The 83-base-pair (bp) and 479-bp PCR products correspond to CD44s (standard form) and CD44v8-10 (variant form containing sequences from variant exons 8,9, and 10), respectively. Transcripts (cDNAs) from HT29 human colon cancer cells were used as a positive control template in this analysis. M ‫ס‬ molecular weight markers (1-kilobase ladder; Life Technologies, Inc., Gaithersburg, MD). C) RT-PCR analysis of CD44 variant expression in leukocytes obtained from five healthy volunteers was performed using primers S1 and AS1. The PCR products were electrophoresed in an 8% polyacrylamide gel and then silver stained. The 83-bp and 287-bp PCR products correspond to CD44s and CD44v10 (variant form containing sequences from variant exon 10), respectively.
scripts using a conventional RT-PCR method. However, one of the major problems encountered in using PCR technique has been its high sensitivity, which enables the detection of trivial amounts of CD44v8-10 transcripts expressed in non-neoplastic cells such as leukocytes, thereby making it difficult to distinguish cancer cells from the normal cells (data not shown). Therefore, we had to develop an alternative method for quantifying the CD44v8-10 overabundantly expressed in cancer cells in clinical samples.
We examined CD44 variant expression in leukocytes, which are major cell components in various body fluids. RT-PCR analysis using the S1 and AS1 primers showed that, in addition to the 83-base-pair (bp) amplification product corresponding to CD44s, another larger product was found in leukocytes obtained from healthy volunteers (Fig. 1, C) . Direct DNA sequence analysis revealed that the larger product corresponded to CD44v10, which contains variant exon 10. Thus, our findings demonstrated that normal leukocytes predominantly expressed CD44s and CD44v10, whereas colon, lung, and bladder carcinomas mainly expressed CD44s and CD44v8-10. Furthermore, it evoked our great interest that the first three nucleotides (ATA) of the CD44 variant exon 10 (v10) were found to be identical to those of the variant exon 8 (v8). By use of this sequence identity, we designed a set of primers (S2 and AS2) to co-amplify both CD44v8-10 and CD44v10 cDNA, as shown in Fig. 2 , A. The size of CD44v10 cDNA amplified with these primers is 238 bp, whereas that of CD44v8-10 cDNA amplified with the same set of primers is 430 bp. We examined whether RT-PCR would allow us to quantify the relative expression levels of CD44v8-10 and CD44v10 transcripts.
First, messenger RNA extracted from normal leukocytes was subjected to RT-PCR using the S2 and AS2 primers. CD44v10 transcripts were predominantly amplified, and a faint band derived from CD44v8-10 transcripts was also identified. The CD44v8-10/CD44v10 (v8-10/v10) ratio in leukocytes from the seven healthy volunteers remained low with little individual variation (v8-10/v10 ratio ‫ס‬ 0.35 ± 0.03) (Fig. 2, B) . The leukocytes are comprised of peripheral blood mononuclear cells (PBMNCs) and polymorphonuclear cells (PMNs). Accordingly, we examined the v8-10/v10 ratio in PBMNCs and PMNs separately. Both leukocyte types also exhibited similar expression patterns, i.e., CD44v10 transcripts were predominantly amplified (PBMNCs: v8-10/v10 ratio ‫ס‬ 0.29 ± 0.07; PMNs: v8-10/ v10 ratio ‫ס‬ 0.45 ± 0.08 ) (Fig. 2, B) . Taken together, we hypothesized that the existence of cancer cells overexpressing CD44v8-10 mixed with a greater number of leukocytes could significantly elevate the v8-10/v10 ratio.
To examine the validity of the RT-PCR method as a quantitative assay, 2 × 10 6 normal leukocytes were mixed in separate tests with an increasing number (1 × 10 2 to 1 × 10 4 ) of HT29 colon cancer cells and HT1376 bladder cancer cells expressing CD44v8-10. The resultant mixtures were subjected to CC-RT-PCR. As shown in Fig. 3 , when the v8-10/v10 ratios were plotted against the number of added HT29 cells or HT1376 cells, linear relationships were observed. Our data indicated that the relative expression of CD44v8-10 transcripts to CD44v10 transcripts can be quantified by this novel competitive RT-PCR approach using the endogenous CD44v10 transcripts as a source of internal standard competitor RNA. We named this method CD44v8-10/CD44v10 competitive RT-PCR (CC-RT-PCR). The sense primer (S2) was designed to span the splice junction of standard exon 5 and variant exon 8 (arrows). This junction primer is complementary to the contiguous 19 (3Ј) and three (5Ј) nucleotides of the two adjoining exons, respectively. Since the first three nucleotides (ATA) of variant exon 8 are identical to those of variant exon 10, primer S2 anneals not only to the junction of standard exon 5 and variant exon 8 but also to the junction of standard exon 5 and variant exon 10. The antisense primer (AS2) was designed to span the splice junction of variant exon 10 and standard exon 16 (arrows). Primer AS2 is complementary to 17 (3Ј) and five (5Ј) nucleotides of the adjoining exons, respectively. Therefore, primers S2 and AS2 could amplify both CD44v8-10 and CD44v10 transcripts in a competitive manner. B) RT-PCR coamplification of both CD44v8-10 and CD44v10 transcripts isolated from the leukocytes of different healthy volunteers, from peripheral blood mononuclear cells (PBMNCs) and from polymorphonuclear cells (PMNs). Primers S2 and AS2 were used to amplify both transcripts. The 430-base-pair (bp) (CD44v8-10 complementary DNA [cDNA]) and 238-bp (CD44v10 cDNA) PCR products were electrophoresed in 2% agarose gels and were stained with ethidium bromide and visualized with UV light. The intensities of the areas corresponding to the amplimers of CD44v8-10 and CD44v10 were measured with the NIH image 1.60 program (Wayne Rasband Analytics, National Institutes of Health, Bethesda, MD), and the CD44v8-10/ CD44v10 ratios were calculated. The numbers under each lane are the CD44v8-10/CD44v10 ratios. M ‫ס‬ molecular weight markers (1-kb ladder; Life Technologies, Inc., Gaithersburg, MD).
Detection of Cancer Cells in Pleural Effusions by CC-RT-PCR
NSCLC, in which CD44v8-10 is the dominant splice variant, is the leading cause of malignant pleural effusions. Initially, we applied CC-RT-PCR to detect cancer cells exfoliated in pleural effusions. At present, the definitive diagnosis of malignant pleural effusions can only be established by finding cancer cells in the pleural fluids or in pleural tissues. According to this clinical definition, 41 malignant pleural effusions and 34 pleural effusions from patients with benign pulmonary diseases were obtained for CC-RT-PCR analysis at the initial thoracentesis in the course of routine diagnostic evaluation. In 32 of the 34 benign pleural effusions, CD44v10 transcripts were predominantly expressed relative to CD44v8-10 transcripts (v8-10/v10 ratio ‫ס‬ 0.00-0.65). Conversely, 31 of the 41 clinically proven malignant pleural effusions presented a predominant expression of CD44v8-10 transcripts (v8-10/v10 ratio >1.00). These differences in the v8-10/v10 ratio between the malignant and benign samples were statistically significant (Mann-Whitney U test; P<.001), indicating the diagnostic potential (Fig. 4) . If we place the diagnostic cutoff value for the v8-10/v10 ratio at 1.0, which was the mean value of the ratios plus three standard deviations for the benign disease samples, the sensitivity and specificity of the CC-RT-PCR assay for the detection of cancer were 76% (95% confidence interval [CI] ‫ס‬ 63%-90%) and 94% (95% CI ‫ס‬ 86%-100%), respectively.
Cytologic analysis was performed on all 41 samples associated with malignant diseases. Of these 41 samples, three cases had not been definitively diagnosed by the initial cytologic examination and further intensive inspections were required. However, our CC-RT-PCR assay revealed that these three cases (Table 1 ; patients 1-3) predominantly expressed CD44v8-10 transcripts, suggesting the existence of cancer cells in their pleural effusions. Patient 1 was found to have a primary squamous cell carcinoma of the lung with a small pleural effusion. Cytologic examination of the fluid after thoracentesis was negative for cancer. Subsequently, thoracotomy was performed, and the histologic examination of the pleural tissue revealed pleuritis carcinomatosa. In addition, immunohistochemical analysis using the anti-CD44v8-10 antibody demonstrated that the cancer cells in the pleural tissue exhibited strongly positive staining (Fig. 5) . All of these findings supported the result from CC-RT-PCR applied to the initial thoracentesis sample. Patient 2, who had had a resected breast carcinoma 10 years previously, developed a pleural effusion on the side opposite to the primary lesion. Cytologic examination resulted in difficulty in interpreting whether the suspicious cells in the pleural effusion were reactive mesothelial or cancer cells. Detailed morphologic comparison of the suspicious cells and cancer cells found in the resected primary tumor tissue led to the clinical diagnosis of a malignant pleural effusion due to recurrence of the breast carcinoma.
Patient 3, who had undergone surgery for a laryngeal carcinoma 8 months previously, developed a pleural effusion. The effusion obtained by the initial thoracentesis was cytologically negative for cancer; however, the CC-RT-PCR analysis suggested that the effusion was malignant (v8-10/v10 ratio ‫ס‬ 6 normal peripheral blood leukocytes (PBLs). The resultant mixtures were subjected to CC-RT-PCR analysis. PCR products were analyzed in 2% agarose gels. The numbers under each lane are the CD44v8-10/CD44v10 intensity ratios. B) The CD44v8-10/CD44v10 ratios were plotted against the number of added tumor cells on a log-log scale; ᭺ ‫ס‬ HT29 cell mixtures; ᭹ ‫ס‬ HT1376 cell mixtures. The corresponding linear regression curves showed linear relationships.
1.64). This case was finally diagnosed as a malignant pleural effusion by cytologic examination at the third thoracentesis.
Detection of Cancer Cells in Urine by CC-RT-PCR
Overexpression of CD44v8-10 in bladder carcinomas suggested that the CC-RT-PCR could be used to detect small numbers of exfoliated cancer cells in urine from patients with bladder cancer. Forty spontaneously voided urine samples were obtained for CC-RT-PCR. All of the urine samples from benign diseases (n ‫ס‬ 20) displayed the predominant expression of CD44v10 transcripts (v8-10/v10 ratio ‫ס‬ 0.04-0.43). In contrast, in 15 of the 20 urine samples from patients with bladder cancer, CD44v8-10 was predominantly amplified (v8-10/v10 ratio >1.00). There were significant differences (Mann-Whitney U test; P<.001) in the v8-10/v10 ratio between the malignant and benign samples (Fig. 4) . At our determined cutoff value (v8- 10/v10 ratio ‫ס‬ 1.0), the sensitivity and specificity for cancer diagnosis were 75% (95% CI ‫ס‬ 55%-95%) and 100%, respectively. Notably, eight of these 15 samples with CD44v8-10 predominant expression had been cytologically undiagnosed (Table  1 ; patients 4-11). For patients 4-11, the histologic cancer diagnosis was made later by cystoscopic biopsy of suspicious bladder lesions. These results showed that in the urine as well as in pleural effusion samples, the v8-10/v10 ratio could be a valuable indicator and serve as an important adjunct to cytology in cancer diagnosis.
Discussion
In this study, we demonstrated that CD44v8-10 was the most dominant CD44 splice variant expressed in NSCLCs and bladder carcinomas and could be a useful marker in cancer diagnosis. On the basis of these findings, we developed a novel molecular approach, CD44v8-10/CD44v10 competitive RT-PCR (CC-RT-PCR) for the detection of cancer cells overexpressing CD44v8-10 in body fluids.
Interest in CD44 splice variants arose from the discovery that the expression of a CD44 variant containing variant exon 6 (CD44v6) distinguished metastatic from nonmetastatic adenocarcinoma cell lines in the rat (24) . In human cancers, however, contradictory findings have been reported in some tumor types (23, 25, (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) 43 ). CD44v6 appears to be important in the rat model, but its biologic significance in human cancers remains to be elucidated. Instead, association of the other CD44 splice variants with various human cancers has been described. We previously reported that a specific variant, CD44v8-10, was highly expressed in human colon carcinomas compared with adjacent non-neoplastic tissues (44) . Furthermore, we have confirmed the predominant expression of CD44v8-10 in NSCLCs and bladder carcinomas, and other groups have reported consistent findings in breast (34) , gastric (41) , and thyroid (45) carcinomas. In addition, an association between CD44v8-10 expression and tumor progression has been demonstrated in some reports (27, 40, 41, 46) . All these lines of evidence prompted us to develop a molecular detection system using CD44v8-10 as a marker for cancer diagnosis.
Recent studies (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) have demonstrated that PCR methods targeted at tumor-specific genetic abnormalities can detect a small number of cancer cells mixed with a larger number of normal cells. These methods offer considerable promise for the early diagnosis of cancer and the detection of tumor progression before clinically evident metastasis. However, they have not entered into routine clinical application because of several problems. The primary limitation has been the lack of suitable genetic targets common to many solid tumors. Second, some of the reported methods are cumbersome and labor intensive. Additionally, the assessment of the clinical usefulness of some new methods using PCR has been unsatisfactory.
Some reports have suggested that the detection of alterations in CD44 splicing patterns in clinical samples could offer one of the most promising molecular approaches for cancer diagnosis (38, (47) (48) (49) (50) (51) . Since the expression of CD44 splice variants has also been observed in many normal tissues, there have been some misgivings about RT-PCR analysis for the amplification of CD44 splice variants to detect cancer cells specifically (21, 22) . In fact, CD44v8-10, which we chose as the target for PCR amplification, was found to be expressed at low levels in normal epithelial cells (20, 22) . Moreover, we also detected trivial amounts of CD44v8-10 transcripts in normal leukocytes. Therefore, CD44v8-10 appeared at first to be an inappropriate amplification target for the detection of cancer cells. To overcome these difficulties, we developed CC-RT-PCR to quantify the relative expression of CD44v8-10 transcripts to CD44v10 transcripts. The endogenous CD44v10 transcripts, which were identified as the predominant CD44 splice variants in leukocytes, were used as internal standard, competitor RNAs for measuring the expression level of CD44v8-10 transcripts. The use of an endogenous competitor simplified some of the laborious processes in conventional competitive RT-PCR (12) . It was advantageous in examining many clinical samples, with results being available within 1 day. However, CC-RT-PCR still has some drawbacks, such as requiring rapid RNA extraction, triplicated independent PCR reactions, and manual image analysis. Further simplification and automation of these steps would allow the assay to be more clinically useful.
The CC-RT-PCR assay applied to pleural effusion and urine samples showed that the v8-10/v10 ratios in the samples associated with malignant diseases were significantly higher than those associated with benign diseases. One concern was that alterations in CD44 splicing patterns might occur in background nonmalignant cells, including activated leukocytes, mesothelial cells, or urothelial cells, and that the v8-10/v10 ratio might display large fluctuations. However, the v8-10/v10 ratios were consistently low in various benign diseases, including inflammatory diseases. These data suggested that the v8-10/v10 ratio was a useful marker for cancer diagnosis.
The presence of pleural effusions in the setting of cancer is an ominous sign. The existence of cancer cells in pleural effusions should be determined to properly stage the tumor, thereby allowing institution of the appropriate therapeutic approaches. At present, the diagnosis of malignant pleural effusions must be documented by positive results on cytologic examination, per- cutaneous pleural biopsy, or thoracoscopy. Although cytologic diagnosis is highly specific and rarely brings false-positive results, high false-negative rates have been reported. In various reports, the percentage of cases in which the cytologic examination of pleural fluids established the diagnosis of malignant pleural effusions ranged from 40% to 87% (52, 53) . Definitive diagnosis may be difficult, chiefly as a result of the cytologically atypical changes that can occur in reactive mesothelial cells. Repeated thoracentesis or a closed pleural biopsy do not significantly increase the diagnostic yield for cancer. Recently, in the case of undiagnosed pleural effusions, rigid thoracoscopy has been recommended (54) . But this procedure is invasive, requiring an operating suite and expert technique. CC-RT-PCR is a noninvasive examination that does not require an experienced specialist. Combination of the CC-RT-PCR assay and a cytologic examination can increase the true-positive yield for cancer diagnosis without performing additional invasive diagnostic procedures.
Urinary cytology is the most common examination method for the initial diagnosis of bladder cancer and the detection of postoperative recurrence; yet, it is known to miss up to 50% of tumors (55) (56) (57) . Cystoscopy, which is the ''gold standard'' for diagnosis, is invasive and too expensive for routine examinations. Therefore, there is a pressing need for more sensitive and less invasive diagnostic tools. Sensitive detection of cancer cells in voided urine, which can be performed before cystoscopic examination, can help to establish the early diagnosis of bladder cancer.
The CC-RT-PCR assay is a rapid, sensitive, and specific test that was able to detect a sparse population of cancer cells overexpressing CD44v8-10 among a much larger population of nonneoplastic cells in body fluids, i.e., pleural effusions and urine. Since overexpression of CD44v8-10 was found in the majority of human cancers, CC-RT-PCR may find further application to other biologic samples beyond pleural effusions and urine. We hope that CC-RT-PCR may be applied for practical clinical examinations after confirmation in larger trials.
